Literature DB >> 29019147

MRI and multiple sclerosis-the evolving role of MRI in the diagnosis and management of MS: a clinician's perspective.

H Kearney1, A M Cahalane2, R P Killeen2, C McGuigan3.   

Abstract

The diagnosis of multiple sclerosis (MS) is based on a history consistent with demyelination of the central nervous system and corresponding physical signs on examination. However, this diagnosis is supported radiologically using magnetic resonance imaging (MRI). At present, MRI serves as the most reliable and widely available biomarker for the practising clinician to measure disease activity and treatment response in MS. As MRI remains central to both the diagnosis and management of MS, this paper provides proposed guidelines for its use in routine clinical practice.

Entities:  

Keywords:  Disease-modifying drugs; MRI; MS; PML

Mesh:

Year:  2017        PMID: 29019147     DOI: 10.1007/s11845-017-1691-z

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  27 in total

Review 1.  Primary progressive multiple sclerosis.

Authors:  A J Thompson; C H Polman; D H Miller; W I McDonald; B Brochet; X Filippi M Montalban; J De Sá
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

Review 2.  Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

Authors:  Gavin Giovannoni; Benjamin Turner; Sharmilee Gnanapavan; Curtis Offiah; Klaus Schmierer; Monica Marta
Journal:  Mult Scler Relat Disord       Date:  2015-05-08       Impact factor: 4.339

3.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

Review 4.  Optical coherence tomography in multiple sclerosis.

Authors:  Elliot Frohman; Fiona Costello; Robert Zivadinov; Olaf Stuve; Amy Conger; Heather Winslow; Anand Trip; Teresa Frohman; Laura Balcer
Journal:  Lancet Neurol       Date:  2006-10       Impact factor: 44.182

5.  Scoring treatment response in patients with relapsing multiple sclerosis.

Authors:  M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano
Journal:  Mult Scler       Date:  2012-09-25       Impact factor: 6.312

6.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

7.  Early MRI in optic neuritis: the risk for disability.

Authors:  J K Swanton; K T Fernando; C M Dalton; K A Miszkiel; D R Altmann; G T Plant; A J Thompson; D H Miller
Journal:  Neurology       Date:  2009-02-10       Impact factor: 9.910

8.  Comparison of multiple sclerosis lesions at 1.5 and 3.0 Tesla.

Authors:  Nancy L Sicotte; Rhonda R Voskuhl; Seth Bouvier; Rochelle Klutch; Mark S Cohen; John C Mazziotta
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

Review 10.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

View more
  2 in total

1.  Quantitative magnetic resonance assessment of brain atrophy related to selected aspects of disability in patients with multiple sclerosis: preliminary results.

Authors:  Ewelina Marciniewicz; Anna Pokryszko-Dragan; Przemysław Podgórski; Krzysztof Małyszczak; Anna Zimny; Anna Kołtowska; Sławomir Budrewicz; Marek Sąsiadek; Joanna Bladowska
Journal:  Pol J Radiol       Date:  2019-04-02

Review 2.  Outcome measures assisting treatment optimization in multiple sclerosis.

Authors:  Gabriel Pardo; Samantha Coates; Darin T Okuda
Journal:  J Neurol       Date:  2021-08-02       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.